TY  - JOUR 
AU  - García-Alfonso, P.
AU  - Saiz Rodríguez, Miriam
AU  - Mondéjar, R.
AU  - Salazar, J.
AU  - Páez, D.
AU  - Borobia, A. M.
AU  - Safont, M. J.
AU  - García-García, I.
AU  - Colomer, R.
AU  - García-González, X.
AU  - Herrero, M. J.
AU  - López-Fernández, L. A.
AU  - Abad-Santos, F.
PY  - 2022
SN  - 1699-048X
UR  - https://hdl.handle.net/10259/11925
AB  - 5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This...
LA  - eng
PB  - Springer Nature
KW  - 5-fluorouracil
KW  - Capecitabine
KW  - Dihydropyrimidine dehydrogenase
KW  - Genotypes
KW  - Pharmacogenetics
KW  - Toxicity
KW  - Farmacogenómica
KW  - Pharmacogenomics
TI  - Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines
DO  - 10.1007/s12094-021-02708-4
T2  - Clinical and Translational Oncology
VL  - 24
M2  - 483
ER  -